Transforming Discovery into Opportunity

CDRD spin-off companies, Zucara TherapeuticsSepset Biosciences, have been chosen to present at Dose of the Valley in San Francisco on February 9/10.

Read more…

We are very pleased to announce that Karimah Es Sabar, our President and CEO, will receive a 2016 Influential Women in Business Award!

Read more…

Introducing Zucara Therapeutics Inc., a new start-up company created by MaRS Innovation and CDRD.

Zucara is developing a novel drug therapy to reduce the severity and frequency of hypoglycemic (low blood sugar) episodes in people with diabetes.

Read more…

Kairos Therapeutics Inc., a CDRD spin-out company, has entered into a strategic partnership with Zymeworks!

Read more…

Thanks to Minister Terry Lake for visiting our labs to see first hand how we are successfully bridging the commercialization gap between academia and industry, and translating research discoveries into new therapies for patients.

CDRD & AstraZeneca Canada highlighted some of the excellent Canadian diabetes research and connected researchers to industry during the International Diabetes Federation World Congress recently held in Vancouver.

CDRD is a proud supporter of Women Against Multiple Sclerosis (WAMS) through the MS Society of Canada.

Thank you to everyone who helped fundraise and support research to #endMS!

CDRD & the University of Saskatchewan have teamed up to develop a blood test that could contribute to a faster and more effective diagnosis of  traumatic brain injuries, commonly known as concussions.

Read more…

A new type of cancer therapy based on seemingly unrelated elements of malaria and cancer is showing promise for development.

Kairos Therapeutics, a local biotech company spun-out of CDRD, has partnered with VAR2 Pharmaceuticals to advance the technology into clinical trials.

Read more…

Find out how CDRD can now support Canadian Health Sciences Companies…..

Read more about our Opportunities for Industry……

CDRD is headquartered in the award-winning UBC Pharmaceutical Sciences Building.

CDRD BY THE NUMBERS:

  • Over 1,100 early-stage technologies evaluated for commercial potential
  • Over 200 projects on 134 distinct technologies
  • 56 technologies advanced toward commercialization and/or commercialized
  • 5 spin-off companies launched
  • 5 technologies out-licensed

What is CDRD?

Headquartered in Vancouver, British Columbia, The Centre for Drug Research and Development (CDRD) is Canada’s national drug development and commercialization engine.

We work in partnership with academia, industry, government and foundations, to provide the specialized expertise and infrastructure to identify and de-risk promising discoveries generated by health-related research, and transform them into commercially viable investment opportunities for the private sector – and ultimately into innovative new therapies for patients.

In doing so, CDRD is actively growing our national health sciences industry into a wholly-optimized generator of economic prosperity for the country.

Since 2008, Canada’s Networks of Centres of Excellence Program has recognized CDRD as a Centre of Excellence for Commercialization and Research (CECR).

Latest from the Blog

CDRD’s Co-Scientific Director finds Duchenne muscular dystrophy is a stem cell disease

A Summer of Change and New Autumn Beginnings

+ VISIT THE BLOG

Latest from Twitter


+ FOLLOW US ON TWITTER



A Shared Vision










  • Industry
  • Academia
  • Government

Sign up to our newsletter

Receive CDRD's e-newsletter, The CDRD Pipeline and other e-communications for regular updates on all our news and activities.



© Copyright 2016 CDRD. All rights reserved.